PPARGC1A and prostate carcinoma: To determine whether this effect of PGC-1α inhibition extends beyond the PARCB-derived cell lines, we first examined its effect on PRNBSA-induced SCN prostate cancer progression (model described in SI Appendix, Fig. S7B).